Evelo Biosciences Revenue and Competitors

Boston, MA USA

Location

$281.5M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Evelo Biosciences's estimated annual revenue is currently $27M per year.(i)
  • Evelo Biosciences's estimated revenue per employee is $599,333
  • Evelo Biosciences's total funding is $281.5M.
  • Evelo Biosciences's current valuation is $295.1M. (January 2022)

Employee Data

  • Evelo Biosciences has 45 Employees.(i)
  • Evelo Biosciences grew their employee count by -62% last year.

Evelo Biosciences's People

NameTitleEmail/Phone
1
Chief Financial OfficerReveal Email/Phone
2
CSOReveal Email/Phone
3
CEOReveal Email/Phone
4
VP, Program and Vendor ManagementReveal Email/Phone
5
SVP, Head ResearchReveal Email/Phone
6
VP, Intellectual PropertyReveal Email/Phone
7
VP, Head Corporate Development and Strategic IntegrationReveal Email/Phone
8
Director StatisticsReveal Email/Phone
9
Director, In Vivo PharmacologyReveal Email/Phone
10
Chief Technology & Quality OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Evelo Biosciences?

Evelo Biosciences, Inc. is a clinical stage biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects. These cells in the small intestine play a central role in governing the immune, metabolic and neurological systems. The company?s first product candidates are monoclonal microbials, single strains of microbes selected for defined pharmacological properties. They have been observed in preclinical models to have systemic dose-dependent effects, modulating multiple clinically validated pathways. Evelo?s therapies have the potential to be effective, safe and affordable medicines to improve the lives of people with chronic disease and cancer. Evelo currently has three product candidates, EDP1066 and EDP1815 for the treatment of inflammatory diseases and EDP1503 for the treatment of cancer. Evelo is also advancing additional oral biologics through preclinical development in other disease areas.

keywords:N/A

$281.5M

Total Funding

45

Number of Employees

$27M

Revenue (est)

-62%

Employee Growth %

$295.1M

Valuation

N/A

Accelerator

Evelo Biosciences News

2022-04-19 - Where Does Wall Street Think Evelo Biosciences Inc (EVLO) Stock Will Go?

On average, analysts give Evelo Biosciences Inc a Strong Buy rating. The average price target is $19.1, which means analysts expect the stock to...

2022-04-17 - Evelo Biosciences Appoints John Maraganore, Ph.D. and ...

Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small...

2022-04-13 - Evelo Biosciences Provides Updated Guidance on Advancing ...

Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small...

2019-07-25 - Evelo Biosciences Secures $45M Debt Financing from K2 HealthVentures

CAMBRIDGE, Mass., July 25, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects, today announced that it has entered into a loan and security agreement for up ...

2018-04-14 - Flag­ship’s Evelo Bio­sciences pitch­es $100M IPO for a new plat­form of mon­o­clon­al mi­cro­bials

Sim­ba Gill With its lead “mon­o­clon­al mi­cro­bial” about to be test­ed for the first time on a hu­man, Evelo Bio­sciences be­lieves that this is the right time to float a $100 mil­lion IPO. Launched with $85.4 mil­lion raised from the sale of stock to Flag­ship and a loan from Pa­cif­ic Wes ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.6M45-6%$128.2M
#2
$3.5M4518%N/A
#3
$12.7M45-18%N/A
#4
$3.7M4518%N/A
#5
$9M45-13%N/A